business
AstraZeneca Reports Positive Data For Tozorakimab From Phase III OBERON, TITANIA Trials In COPD
AstraZeneca PLC (AZN) announced positive results from the Phase III OBERON and TITANIA trials evaluating Tozorakimab in chronic obstructive pulmonary disease (COPD).
Read full article on Rttnews